Advances in the development of antimicrobial peptides and proteins for inhaled therapy.
Administration, Inhalation
Animals
Anti-Bacterial Agents
/ administration & dosage
Antimicrobial Peptides
/ administration & dosage
Chemistry, Pharmaceutical
/ methods
Drug Development
/ methods
Drug Resistance, Multiple, Bacterial
Drug Synergism
Humans
Proteins
/ administration & dosage
Tissue Distribution
Antimicrobial peptides and proteins (APPs)
Inhaled therapeutics
Multidrug-resistant bacteria
Respiratory infections
Journal
Advanced drug delivery reviews
ISSN: 1872-8294
Titre abrégé: Adv Drug Deliv Rev
Pays: Netherlands
ID NLM: 8710523
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
27
09
2021
revised:
18
11
2021
accepted:
18
11
2021
pubmed:
24
11
2021
medline:
3
3
2022
entrez:
23
11
2021
Statut:
ppublish
Résumé
Antimicrobial peptides and proteins (APPs) are becoming increasingly important in targeting multidrug-resistant (MDR) bacteria. APPs is a rapidly emerging area with novel molecules being produced and further optimised to enhance antimicrobial efficacy, while overcoming issues associated with biologics such as potential toxicity and low bioavailability resulting from short half-life. Inhalation delivery of these agents can be an effective treatment of respiratory infections owing to the high local drug concentration in the lungs with lower exposure to systemic circulation hence reducing systemic toxicity. This review describes the recent studies on inhaled APPs, including in vitro and in vivo antimicrobial activities, toxicity assessments, and formulation strategies whenever available. The review also includes studies on combination of APPs with other antimicrobial agents to achieve enhanced synergistic antimicrobial effect. Since different APPs have different biological and chemical stabilities, a targeted formulation strategy should be considered for developing stable and inhalable antimicrobial peptides and proteins. These strategies include the use of sodium chloride to reduce electrostatic interaction between APP and extracellular DNA in sputum, the use of D-enantiomers or dendrimers to minimise protease-mediated degradation and or the use of prodrugs to reduce toxicity. Although great effort has been put towards optimising the biological functions of APPs, studies assessing biological stability in inhalable aerosols are scarce, particularly for novel molecules. As such, formulation and manufacture of inhalable liquid and powder formulations of APPs are underexplored, yet they are crucial areas of research for clinical translation.
Identifiants
pubmed: 34813794
pii: S0169-409X(21)00459-2
doi: 10.1016/j.addr.2021.114066
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Antimicrobial Peptides
0
Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
114066Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.